Company record · updated October 7, 2026
Electra Therapeutics, Inc.: 3 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs August 28, 2026 to August 28, 2026.
3observations
1source filings
3verified rows
2026-08-28most recent as-of date
Source rails for this company: S-1 charter round (3).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2026-08-28 | Series C price per share | 6.7688 USD | — | VERIFIED | "Original Issue Price" defined for Series C | 000119312526374259 |
| 2026-08-28 | Series B price per share | 9.0251 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000119312526374259 |
| 2026-08-28 | Series A price per share | 1.5375 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000119312526374259 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price.